HC Wainwright & Co. Reiterates Buy on Jazz Pharmaceuticals, Maintains $204 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Oren Livnat has reiterated a 'Buy' rating on Jazz Pharmaceuticals, maintaining a price target of $204.
August 11, 2023 | 10:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jazz Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co., with a maintained price target of $204.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Jazz Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100